Sponsor Pipeline

Ultragenyx Pharmaceutical Inc Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
18
Active Trials
4
Recruiting
9
Phase 3
5
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT02716246
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
date change Primary completion pushed: 2027-07 -> 2029-03
2026-06-12 NCT02716246
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
date change Completion pushed: 2027-07 -> 2029-03
2026-06-12 NCT03604835
Mucopolysaccharidosis VII Disease Monitoring Program
date change Primary completion moved earlier: 2033-05 -> 2032-04
2026-06-12 NCT03604835
Mucopolysaccharidosis VII Disease Monitoring Program
date change Completion moved earlier: 2033-05 -> 2032-04
2026-06-03 NCT05345171
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC)…
Enrollment increased: 32 -> 37 participants
Active Trials by Phase
Phase 3
7
Phase 2/3
2
Phase 2
1
Phase 1/2
2
Not specified
6
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05768854 Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Osteogenesis Imperfecta Active, Not Recruiting
NCT06636071 Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Osteogenesis Imperfecta Active, Not Recruiting
NCT05933200 A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in… Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Active, Not Recruiting
NCT04360265 Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for… Mucopolysaccharidosis IIIA Enrolling by Invitation
NCT06415344 Long-term Extension of GTX-102 in Angelman Syndrome Angelman Syndrome Enrolling by Invitation
NCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome… Angelman Syndrome Active, Not Recruiting
NCT05345171 Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC)… OTC Deficiency Active, Not Recruiting
Phase 2/3
NCT02716246 Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH MPS IIIA Recruiting
NCT05125809 Setrusumab vs Placebo for Osteogenesis Imperfecta Osteogenesis Imperfecta Active, Not Recruiting
Phase 2
NCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type… Angelman Syndrome Recruiting
Phase 1/2
NCT04884815 A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease Wilson Disease Active, Not Recruiting
NCT07511556 First-in-human Study of UX016 in GNEM GNE Myopathy Not Yet Recruiting
Not specified
NCT06636383 Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program Glycogen Storage Disease Type Ia Recruiting
NCT03604835 Mucopolysaccharidosis VII Disease Monitoring Program Mucopolysaccharidosis VII Recruiting
NCT03651505 X-linked Hypophosphatemia Disease Monitoring Program X-linked Hypophosphatemia Active, Not Recruiting
NCT03636438 Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency Ornithine Transcarbamylase (OTC) Deficiency Active, Not Recruiting
NCT04632953 Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Active, Not Recruiting
NCT04783428 Tumor-induced Osteomalacia Disease Monitoring Program Tumor-induced Osteomalacia (TIO) Active, Not Recruiting
Get alerts when Ultragenyx Pharmaceutical Inc's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free